ERBB2 and neoplasm: Motivated by these findings, we investigated the antitumor capabilities of HER2-CAR-targeted NK cells in three-dimensional tumor spheroids (Figure 3a) originating from both trastuzumab-resistant (JIMT-1) and sensitive (N87) cell lines (Figure 3b).